RxDoctor Payments Data

Frank Jircik, MD

Internal Medicine · Burleson, TXNPI 1497711840

Payments from drug & device makers

$1,356in general payments, 2019–2025

Across 89 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$658
  • Pfizer$211
  • Dexcom, Inc.$69
  • Sumitomo Pharma America, Inc.$51
  • Abbott$44
  • C2n Diagnostics, LLC$43
  • plus $279 from 15 others

What the payments were for

  • Food & beverage$1,356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,356 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$339,260
Medicare patients
611
Services billed
4,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$189,873
EliquisApixaban77$91,453
OzempicSemaglutide45$56,064
JardianceEmpagliflozin49$51,361
LinzessLinaclotide56$47,444
Tresiba Flextouch U-200Insulin Degludec14$32,868
XareltoRivaroxaban32$30,469
TrulicityDulaglutide14$29,015
MounjaroTirzepatide31$28,652
MyrbetriqMirabegron32$27,123
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen602$18,038
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$16,878
Tresiba Flextouch U-100Insulin Degludec13$9,760
SymbicortBudesonide/Formoterol Fumarate20$8,700
InvokanaCanagliflozin12$8,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$211$99,06790 claims
Novo NordiskOzempic$20$56,06445 claims
AbbVieLinzess, Synthroid$658$50,701111 claims
Johnson & JohnsonXarelto, Invokana$14$38,80644 claims
GSKAnoro Ellipta, Arnuity Ellipta$17$20,87938 claims
AstraZenecaSymbicort$12$8,70020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →